PMC:7228307 / 380-594 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"21","span":{"begin":203,"end":207},"obj":"Gene"}],"attributes":[{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Gene:2213"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediat"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":203,"end":205},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediat"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T4","span":{"begin":57,"end":66},"obj":"http://purl.obolibrary.org/obo/IDO_0000528"}],"text":"are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediat"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"21","span":{"begin":203,"end":207},"obj":"Gene"}],"attributes":[{"id":"A21","pred":"pubann:denotes","subj":"21","obj":"Gene:2213"}],"text":"are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediat"}